Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 10, Issue 3, Pages 221-237Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd3373
Keywords
-
Funding
- Ligue Nationale contre le Cancer (Equipes labellisee)
- Agence Nationale pour la Recherche (ANR)
- European Commission
- Fondation pour la Recherche Medicale (FRM)
- Institut National du Cancer (INCa)
- Canceropole Ile-de-France
- AXA Chair for Longevity Research
- US National Institutes of Health
- National Institute of Aging (USA)
- National Cancer Institute (USA)
Ask authors/readers for more resources
Cell death has an important role in many human diseases, and strategies aimed at modulating the associated pathways have been successfully applied to treat various disorders. Indeed, several clinically promising cytotoxic and cytoprotective agents with potential applications in cancer, ischaemic and neurodegenerative diseases have recently been identified by high-throughput screening (HTS), based on appropriate cell death assays. Given that different cell death modalities may be dysregulated in different diseases, it is becoming increasingly clear that such assays need to not only quantify the extent of cell death, but they must also be able to distinguish between the various pathways. Here, we systematically describe approaches to accurately quantify distinct cell death pathways, discuss their advantages and pitfalls, and focus on those techniques that are amenable to HTS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available